Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase

MJ Siedner, MA Moorhouse, B Simmons… - Nature …, 2020 - nature.com
Little is known about the impact of pretreatment drug resistance (PDR) on the efficacy of
second generation integrase inhibitors. We sequenced pretreatment plasma specimens …

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

HT Pham, T Mesplède - Expert opinion on pharmacotherapy, 2019 - Taylor & Francis
Introduction: Current antiretroviral therapy is more effective and simpler than in previous
times due to the development of new drugs with improved pharmacokinetic and …

Pre-treatment integrase inhibitor resistance and natural polymorphisms among HIV-1 subtype C infected patients in Ethiopia

DA Arimide, ZI Szojka, K Zealiyas, A Gebreegziabxier… - Viruses, 2022 - mdpi.com
Dolutegravir-based antiretroviral therapy (ART) has been scaled up in many developing
countries, including Ethiopia. However, subtype-dependent polymorphic differences might …

Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited …

ENJ Semengue, D Armenia, S Inzaule… - Journal of …, 2021 - academic.oup.com
Background Transition to dolutegravir-based regimens in resource-limited settings (RLS)
requires prior understanding of HIV-1 integrase variants and conserved regions. Therefore …

Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding

R Chitongo, AE Obasa, SG Mikasi, GB Jacobs… - PLoS …, 2020 - journals.plos.org
Resistance associated mutations (RAMs) threaten the long-term success of combination
antiretroviral therapy (cART) outcomes for HIV-1 treatment. HIV-1 Integrase (IN) strand …

Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy

V Kouamou, J Manasa, D Katzenstein, AM McGregor… - Aids, 2019 - journals.lww.com
Objectives: The integrase strand inhibitor dolutegravir (DTG) combined with tenofovir and
lamivudine (TLD) is a single tablet regimen recommended for 1st, 2nd and 3rd-line public …

Structural implications of genotypic variations in HIV-1 integrase from diverse subtypes

L Rogers, AE Obasa, GB Jacobs… - Frontiers in …, 2018 - frontiersin.org
Human immunodeficiency virus type 1 (HIV-1) integrase (IN) integrates viral DNA into the
host genome using its 3′-end processing and strand-transfer activities. Due to the …

Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first-and second-line ART in Tanzania

S Henerico, E Lyimo, AN Makubi… - Journal of …, 2022 - academic.oup.com
Abstract Introduction Sub-Saharan African countries are introducing integrase strand
transfer inhibitors (INSTIs) in their ART programmes as the preferred first-line regimen, and …

Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings

D Armenia, Y Bouba, R Gagliardini, C Gori… - Journal of Clinical …, 2020 - Elsevier
Background Virological response and resistance profile were evaluated in drug-naïve
patients starting their first-line integrase inhibitors (INIs)-based regimen in a clinical setting …

HIV-1 integrase diversity and resistance-associated mutations and polymorphisms among integrase strand transfer inhibitor-naive HIV-1 patients from Cameroon

SG Mikasi, JO Gichana, C Van der Walt… - AIDS research and …, 2020 - liebertpub.com
The World Health Organization (WHO) has put forth recommendations for the use of
integrase (IN) strand transfer inhibitors (INSTIs) to be part of the first-line combination …